Titlebook: Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Anal; Selected Papers from Jianchang Lin,Bu

Espionage

书目名称Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Anal影响因子(影响力)




书目名称Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Anal影响因子(影响力)学科排名




书目名称Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Anal网络公开度




书目名称Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Anal网络公开度学科排名




书目名称Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Anal被引频次




书目名称Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Anal被引频次学科排名




书目名称Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Anal年度引用




书目名称Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Anal年度引用学科排名




书目名称Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Anal读者反馈




书目名称Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Anal读者反馈学科排名

TRACE

Sample Size Allocation in a Dose-Ranging Trial Combined with PoCand ethical concerns may limit the total sample size for the trial. This manuscript discusses various ways of allocating the sample size to each treatment group, under a given total sample size; as well as the performance of different contrast test for PoC.

labile

Infant

2199-0980 analysis.  Each papers was peer-reviewed by at least two referees and also by an editor.  The conference was attended by over 400 participants from academia, industry, and government agencies around the world, including from North America, Asia, and Europe..978-3-319-82610-3978-3-319-42568-9Series ISSN 2199-0980 Series E-ISSN 2199-0999

hysterectomy

Optimal Biomarker-Guided Design for Targeted Therapy with Imperfectly Measured Biomarkersizes the overall response rate for all the patients enrolled in the trial. We develop a likelihood ratio test to evaluate the subgroup treatment effects at the end of the trial. Simulation studies show that the proposed optimal designs achieve our design goal and obtain desirable operating characteristics.

碎片

NOTCH

Bayesian Integration of In Vitro Biomarker to Analysis of In Vivo Safety Assessmentn animal studies. In this chapter, we extend on the previous work by Chiang and Wang (Stat Biopharm Res 7:66–75, 2015) to further investigate how in vitro data can be integrated by the proposed approach and how decisions concerning QT prolongation can be more informatively made for drugs moving from pre-clinical to clinical evaluation.

无法取消

Personalized Effective Dose Selection in Dose Ranging Studieswill be useful for identifying the respondent subgroups and their accompanying doses for the future study design. We illustrate the proposed method with simulation studies. Our method compares favorably to two ad-hoc approaches.

Germinate

Assessing Benefit and Consistency of Treatment Effect Under a Discrete Random Effects Model in Multinder DREM, we consider the concept of the Method 2 in “Basic Principles on Global Clinical Trials” guidance to construct the probability function of benefit and consistency. We also optimize the sample size allocation to reach maximum power for the benefit and consistency.

保守党